RESUMO
OBJECTIVES: The aim of the study was to understand which human papillomavirus (HPV) types are involved in external genital warts (GWs) in a group of Argentinian women in Buenos Aires. METHODS: One hundred sixty consecutive women 15 to 45 years old with GWs were enrolled. All patients underwent confirmatory biopsy. In 150 of 160 patients, the diagnosis of GWs was confirmed by histology, DNA-HPV was investigated using polymerase chain reaction, and sequence analysis with generic primers MY09/11 was performed. RESULTS: HPV 6 and/or 11 was detected in 93.3% patients (140/150). HPV 6 was by far the most common type (80%), followed by HPV 11 (12.7%). Coinfection with these 2 types occurred in 0.7%. HPV 16 was found in 2% and HPV 73 in 0.7%. CONCLUSION: HPV 6 and/or 11 are present in 93.3% (95% confidence interval, 0.9-1.0) of external genital warts in a group of Argentinian women in Buenos Aires and, therefore, could be prevented with HPV vaccine (NCT 015998779).
Assuntos
Condiloma Acuminado/epidemiologia , Condiloma Acuminado/virologia , Genótipo , Papillomaviridae/classificação , Papillomaviridae/isolamento & purificação , Adolescente , Adulto , Argentina/epidemiologia , Biópsia , DNA Viral/genética , DNA Viral/isolamento & purificação , Feminino , Histocitoquímica , Humanos , Pessoa de Meia-Idade , Papillomaviridae/genética , Reação em Cadeia da Polimerase , Prevalência , Análise de Sequência de DNA , Adulto JovemRESUMO
In the present study, the molecular characterization of HPV variants 16, 18, 31, 58, 6 and 11 within the MY06/MY11 L1 genomic region was performed in 128 sequences. For HPV 16, all of the sequences analyzed had a 3 nucleotide insertion resulting in the insertion of serine in the L1 protein sequence; and 4 sequences had at least one single nucleotide polymorphism (SNP). Twelve base substitutions were detected in HPV 58, 6 SNPs produced amino acid changes, and the other SNPs detected were found to be silent mutations. For HPV 31, 25 SNPs were detected as silent mutations. Of the 8 SNPs detected on HPV 18, three produced amino acid changes, the remaining SNPs detected were silent mutations. For HPV 6, 10 SNPs were detected and none of them produced amino acid changes. From the 16 sequences analyzed for HPV 11, two SNPs were detected and neither of them produced amino acid substitutions. Phylogenetic trees were constructed for HPV 16, HPV 18, HPV 31, HPV 58, HPV 6 and HPV 11. In the current study 8 new variants were identified based on sequencing of the L1 region. Changes in the L1 region of the HPV genome may be important for discriminating the infectious potential of different variants, as well as in defining epitopes relevant to vaccine design. The findings of this study indicate that there are new variants of HPV circulating in Argentina, which need to be confirmed by further analyses of the complete HPV genome.
RESUMO
Inicialmente el virus de influenza A(H1N1)pdm09 fue susceptible a los inhibidores de neuraminidasa oseltamivir y zanamivir. Las cepas virales resistentes presentan una sustitución que produce un cambio del aminoácido histidina (H) por una tirosina (Y) en el codón 274 del gen de la neuroaminidasa. El objetivo del trabajo fue realizar un análisis retrospectivo de los resultados obtenidos en muestras estudiadas para influenza A durante el periodo junio - agosto de 2013 y en las muestras positivas determinar la presencia de la mutación H274Y. Se estudiaron 1783 muestras de pacientes con diagnóstico presuntivo de influenza A(H1N1)pdm09, 171 (9.6%) resultaron positivas, a estas se les estudió la presencia de la mutación H274Y. Únicamente dos muestras presentaron la mutación de resistencia. Los métodos para detectar cepas de infuenza A(H1N1)pdm09 resistentes son necesarios para ayudar a los médicos en la selección de la terapia antiviral apropiada de la influenza.
Initially the circulating influenza virus A(H1N1)pdm09 was susceptible to neuraminidase inhibitors oseltamivir and zanamivir. Virtually all resistant viruses possess a substitution at codon 274 of the neuraminidase gene which produces a change of the amino acid histidine (H) to a tyrosine (Y). The aims of the study were to perform a retrospective analysis of samples studied in the Laboratory of Genomic Medicine - MANLAB for influenza A during the period June to August 2013 in Buenos Aires, and to determine the presence of the H274Y mutation. 1783 samples from patients with a presumptive diagnosis of influenza A(H1N1) pdm09 were studied, the virus was detected in 171 samples (9.6%). Then, we studied the presence of the mutation H274Y. Only two samples showed the characteristic resistance mutation. Methods for detecting oseltamivir-resistant A(H1N1)pdm09 influenza strains are needed to assist physicians in the selection of appropriate antiviral therapy for influenza treatment.
Assuntos
Vírus da Influenza A , Vírus da Influenza A Subtipo H1N1 , OseltamivirRESUMO
Mundialmente se han identificado 6 genotipos (1 al 6) del virus de la hepatitis C (HCV). Dichos genotipos se subdividen en diferentes subtipos (a, b, c y otros). La respuesta al tratamiento instaurado depende del genotipo del virus infectante. El objetivo del trabajo fue determinar la frecuencia de los diferentes genotipos del HCV en la población de Argentina. Se estudiaron 510 pacientes infectados con HCV; la genotipificación del virus se realizó utilizando el equipo Versant HCV genotype assay 2.0 (LiPA). Los resultados obtenidos indican que el genotipo predominante del HCV en Argentina es el 1 (67,6%), con una prevalencia similar de subtipos 1a y 1b (33,3% y 34,5%, respectivamente). Se observó también una frecuencia similar de los genotipos 2 y 3 (14,5% cada uno). Con este estudio se actualizan los datos de las frecuencias de los diferentes genotipos de HCV que circulan en Argentina utilizando la nueva versión del reactivo para diagnóstico, el cual permitió una correcta subtipificación de las muestras.
Six hepatitis C virus genotypes have been identified worldwide so far. These genotypes have been subclassified into different subtypes (a, b, c and others). It is known that the response to treatment is highly dependent on the genotype involved. The aim of this work was to assess the frequency of occurrence of the different HCV genotypes in the population of Argentina. To this end, 510 infected patients were subjected to HCV genotyping using the commercial kit Versant HCV genotype assay 2.0. Results indicated that the genotype 1 was the most frequent (67.6%), and that subtypes 1a and 1b showed a similar prevalence (33.3% and 34.5%, respectively). Genotypes 2 and 3 also displayed a similar frequency (14.5% and 14.5% respectively). This study provides an update regarding the frequency of all HCV genotypes circulating in Argentina. The results were obtained by the novel version of the genotyping kit, which enabled a correct subtyping of samples.
Globalmente foram identificados 6 genótipos (1 ao 6) do vírus da hepatite C (HCV). Estes genótipos são subdivididos em vários subtipos (a, b, c, etc.). A resposta ao tratamento depende do genótipo do vírus infectante. O objetivo do estudo foi determinar a freqüência dos diferentes genótipos do HCV na população Argentina. Foram estudados 510 pacientes infectados com o HCV, a genotipagem do vírus foi realizada utilizando o kit Versant HCV genotype assay 2.0 (LiPA). Os resultados obtidos indicam que o genótipo predominante na Argentina é o tipo 1 (67,6%), observando-se uma prevalência dos subtipos 1a e 1b (33,3% e 34,5% respectivamente). Observou-se também uma freqüência semelhante do genótipos 2 e 3 (14,5% e 14,5% respectivamente). Este estudo atualiza os dados das freqüências dos diferentes genótipos do HCV em circulação na Argentina usando a nova versão do kit, o que permitiu uma correta subtipagem das amostras.
Assuntos
Humanos , Hepacivirus/genética , Hepatite C/sangue , Argentina , Genótipo , Hepatite C , Hepatite C/urinaRESUMO
Catecholestrogens are estrogen metabolites formed by hydroxylation of 17beta-estradiol and estrone at either the C-2 or C-4 position, rivaling the parent estrogens in concentration. The objective of the present work was to assess if their catechol group could make them induce proliferation of human breast cancer cells via alpha(2)-adrenoceptors. In competition studies in human breast cancer MCF-7 cells, high concentrations of 2-hydroxy-estradiol (2-OH-E(2)), 2-hydroxy-estrone (2-OH-E(1)) and 4-hydroxy-estrone (4-OH-E(1)) competed for [(3)H]-rauwolscine binding, whereas 4-hydroxy-estradiol (4-OH-E(2)) did not. The contribution of alpha(2)-adrenoceptors and estrogen receptors (ERs) in proliferation enhancement was analyzed with specific antagonists. The specific alpha(2)-adrenergic antagonist yohimbine partially reversed the effect of catecholestrogens except 4-OH-E(2). The selective ER downregulator ICI-182780 or fulvestrant partially or totally reversed the effect of all hydroxylated catecholestrogens. When analyzing the effect of the combination of both antagonists in MCF-7, the contribution of the alpha(2)-adrenoceptors and ERs for 2-OH-E(2), 2-OH-E(1) and 4-OH-E(1) was mixed, whereas for 4-OH-E(2), the only receptor implied was an ER. In MDA-MB-231 cells (ER-alpha negative) the proliferation stimulation by these three catecholestrogens and reversal by the adrenergic antagonist was also observed. It can be concluded that alpha(2)-adrenoceptors contribute at least in part to the mitogenic effect of 2-OH-E(2), 2-OH-E(1) and 4-OH-E(1).